2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2017
Examining motivational interviewing plus nutrition psychoeducation for weight loss in primary care
Barnes RD, Ivezaj V, Martino S, Pittman BP, Paris M, Grilo CM. Examining motivational interviewing plus nutrition psychoeducation for weight loss in primary care. Journal Of Psychosomatic Research 2017, 104: 101-107. PMID: 29275778, PMCID: PMC5774024, DOI: 10.1016/j.jpsychores.2017.11.013.Peer-Reviewed Original ResearchConceptsBinge-eating disorderNutrition psychoeducationMotivational interviewingUsual careAttention control conditionWeight lossPrimary careBasic nutrition informationOverweight/obesityModerate weight lossPsychological improvementPsychoeducationMore weight lossMixed model analysisMixed-model analysisPrognostic significanceTreatment completionScalable combinationCurrent studyPercentage weight lossParticipantsBed statusNutrition informationCareGreater improvement